Group 1 - The Chinese government emphasizes the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry, focusing on original innovation and key core technology breakthroughs [1] - The government aims to leverage artificial intelligence to empower industry development and promote the revitalization of traditional Chinese medicine [1] - BeiGene, a biopharmaceutical company, is recognized for its innovative drug development and commercialization efforts, particularly in cancer treatment [2][3] Group 2 - BeiGene's drug, Brukinsa (百悦泽®), holds the top position in the global BTK inhibitor market and is the only BTK inhibitor approved for five indications [3] - The company is committed to advancing its global presence and aims to achieve multiple research milestones in the next 18 months [3] - BeiGene's leadership emphasizes a new generation of drug development that adheres to scientific research principles [3]
总理调研生物医药产业发展 这家科创板公司在列
Xin Lang Cai Jing·2025-08-21 11:37